A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Key Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Histologically or cytologically confirmed diagnosis of squamous cell carcinoma ofthe esophagus

• Unresectable disease ineligible for curative surgery based on the documented opinionof the qualified medical, surgical or radiation oncologist prior to dCRT and is notexpected to undergo tumor resection during the course of the study

• dCRT treatment according to regional oncology guidelines for esophageal cancer

• Representative archival formalin-fixed, paraffin-embedded (FFPE) tumor specimenscollected prior to initiation of dCRT

• Adequate hematologic and end-organ function prior to randomization

• Women of childbearing potential must remain abstinent or use contraceptive methodswith a failure rate of < 1% per year during the treatment period, for 5 months afterthe final dose of atezolizumab/placebo, and for 90 days after the final dose oftiragolumab/placebo, whichever is later

• Men must agree to remain abstinent (refrain from heterosexual intercourse) or use acondom, and agree to refrain from donating sperm during the treatment period and for 90 days after the final dose of tiragolumab/placebo.

Key Exclusion Criteria:

• Prior treatment with CD137 agonists or immune checkpoint blockade therapies,including anti-CTLA-4, anti-PD-1, anti-PD-L1 and anti-TIGIT therapeutic antibodies

• Any unresolved toxicity of National Cancer Institute's (NCI) Common TerminologyCriteria for Adverse Events (CTCAE) Grade ≥ 2 from the prior chemoradiation therapywith the exception of irreversible and manageable hearing loss

• Prior allogeneic stem cell or solid organ transplantation

• Active or history of autoimmune disease or immune deficiency

• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitisobliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence ofactive pneumonitis

• Malignancies other than esophageal cancer within 2 years prior to screening, withthe exception of malignancies with a negligible risk of metastasis or death

• Treatment with any other investigational agent, including epidermal growth factorreceptor (EGFR) inhibitors, with therapeutic intent for esophageal cancer prior torandomization.